Press

Flatiron Health brings 49+ research acceptances and next-generation capabilities to ASCO 2026

Flatiron Health — Thu, 21 May 2026 21:00:00 GMT

Flatiron's real-world evidence research and live Flatiron Telescope demonstrations at booth #21149 showcase how scale and rigor advance oncology decision-making

New research confirms data quality as the defining priority across the real-world evidence landscape

Flatiron Health — Wed, 20 May 2026 13:00:04 GMT

As oncology grows more complex and the pace of innovation accelerates, life sciences organizations are placing a premium on high-quality, complete, and scalable real-world data. New insights from two independent surveys confirm that data quality and cohort scale are now prerequisites for confident decision-making and insight generation, especially as the industry evolves from retrospective analysis to predictive and AI-driven applications.

Flatiron Health launches Flatiron Telescope, a new AI platform delivering oncology insights in minutes

Flatiron Health — Tue, 19 May 2026 13:00:02 GMT

Accelerates how oncology teams assess study feasibility, size opportunity, and generate real-world intelligence

TailorMed and Flatiron Health Partner to Expand Medication Access and Support Across Oncology Care

Flatiron Health — Mon, 04 May 2026 13:00:05 GMT

Collaboration brings end-to-end medication support to Flatiron’s network, helping community oncology practices connect patients to the resources they need to start and stay on therapy

Flatiron Health and Community Oncology Alliance partner to deliver first comprehensive, real-world assessment of care in community oncology

Flatiron Health — Tue, 28 Apr 2026 12:00:03 GMT

STUDY: Cancer patients experience longer survival in community oncology settings, affirming the high-quality care delivered across community practices

Flatiron Health announces 18 research acceptances featuring the company's real-world data to be presented at ISPOR 2026

Flatiron Health — Wed, 22 Apr 2026 13:00:02 GMT

New research showcases the impact of large language models from extracting nuanced clinical information from unstructured data sources to successfully building digital twin models that simulate patient outcomes under different treatment scenarios

Flatiron Health publishes first peer-reviewed validation framework for AI-extracted real-world oncology data in Journal of Clinical Oncology

Flatiron Health — Mon, 20 Apr 2026 12:59:59 GMT

Three-pillar framework sets methodological benchmark for data quality and transparency in oncology data

Abbott expands access to Precision Oncology portfolio through integration with Flatiron’s OncoEMR® platform

Flatiron Health — Mon, 30 Mar 2026 13:00:00 GMT

Broadens access to Abbott’s Precision Oncology tests across more than 1,600 community cancer care centers and 4,700 providers in Flatiron’s North America network, helping accelerate informed treatment decisions
Allows oncologists to order tests and view results directly in the clinical workflow

Abbott (NYSE: ABT), the global healthcare company, and Flatiron Health, a leading healthtech company advancing point-of-care solutions in oncology, today announced the integration of Abbott’s comprehensive Precision Oncology portfolio into OncoEMR®, Flatiron’s cloud-based Electronic Medical Record (EMR) platform.

Through this integration, oncology providers can now digitally order Abbott tests – individually or in combination – and receive status updates and results directly within their existing OncoEMR clinical workflow. Available Abbott tests include the Oncotype DX Breast Recurrence Score®, OncoExTra®, Oncodetect®, and Riskguard® tests, enabling clinicians to access the comprehensive portfolio through a single, unified experience. This approach supports more informed treatment decisions across multiple stages of cancer care while helping reduce administrative burden and keeping the focus on patient care.

The integration expands access to Abbott’s Precision Oncology tests across Flatiron’s national network of more than 1,600 community cancer care centers, where 4,700 providers deliver care and where most cancer care in the U.S. takes place.

“We’re focused on making it easier for clinicians to access the right information at the right moment of care,” said Quincy Weatherspoon, VP and GM of Point of Care Solutions, Flatiron Health. “By integrating Abbott’s Precision Oncology portfolio directly into OncoEMR, we’re reducing friction in the workflow and helping providers move faster—from test ordering to treatment decisions. This is what it looks like to bring more connected, data-driven care to the point of care.”

“For community oncology practices, where most cancer care is delivered, this removes a key barrier to accessing our portfolio at the point of care, helping accelerate treatment decisions and enabling more informed, personalized patient care,” said Brian Baranick, vice president, Precision Oncology, Abbott.

About Abbott

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 122,000 colleagues serve people in more than 160 countries. Connect with us at abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube.

About Flatiron

Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Through machine learning and AI, real-world evidence, and breakthroughs in clinical trials, we continue to transform patients’ real-life experiences into knowledge and create a more modern, connected oncology ecosystem. Flatiron Health is an independent affiliate of the Roche Group.

Abbott Media

Lisa Warshaw
(323) 360-8778

Abbott Financial

Michael Comilla
(224) 668-1872

Flatiron Media

Nina Toor
press@flatiron.com

Flatiron Health attends the 2026 American Society of Genitourinary Cancers Symposium to answer oncology's most critical questions

Flatiron Health — Mon, 23 Feb 2026 22:00:01 GMT

New research from prostate and bladder cancer Panoramic datasets reveals gaps in treatment implementation, offering pathways for optimized patient-centered care in a rapidly evolving treatment landscape.

Flatiron launches first-of-its-kind AI-powered global prostate cancer datasets

Flatiron Health — Wed, 18 Feb 2026 14:00:03 GMT

Expansion of company’s Panoramic offerings creates a unified gold standard for real-world evidence across the US, UK, and Germany to accelerate R&D pipeline decisions, setting a new standard to answer oncology’s most critical questions

Flatiron Health, a leading healthtech company dedicated to improving cancer care and advancing research using real-world data, today announced their first Panoramic datasets in the UK and Germany for patients with prostate cancer. Globally, prostate cancer affects nearly 1.5 million patients annually and has a rapidly evolving treatment landscape, yet real-world evidence remains limited and infeasible to study across international borders.

Flatiron is the first and only company to deliver global real-world data in this key oncology indication, leveraging proprietary AI and large language model capabilities to build on their Global Evidence Platform. The prostate cancer Panoramic datasets, which encompass the records of nearly 400,000 patients, unlock high-quality, source-level unstructured and structured EHR data across Germany, the UK, and the US. Built on a common data model across all regions, these datasets enable unprecedented interoperability—allowing researchers to seamlessly analyze patient outcomes and treatment patterns across markets to inform global evidence strategies.

"Flatiron is not just adding more data; we are building the singular destination for global oncology intelligence." said Kate Estep, Chief Product Officer at Flatiron Health. "By unifying fragmented global records into a single evidence platform, we are fundamentally changing how our customers develop therapies and—most importantly—when patients can access them."

This launch delivers immediate value to Flatiron's life science customers. The prostate Panoramic dataset builds on already available offerings to create a full scope of understanding for genitourinary cancers, specifically:

The rich data provides all Prostate-Specific Membrane Antigen (PSMA) PET scan data, all prostate-specific antigen (PSA) values across the patient journey, and 19 Homologous Recombination Repair (HRR) genes, plus recurrence and progression details, enabling answers to key questions like how novel therapies are being used and which patients are benefiting most.
Proprietary AI and large language model capabilities that unlock the full scale of the company’s network, with continuous recency to reflect the evolving treatment landscape and capture newly approved treatments as they enter the market.
Unique patient-level EHR data captured through established site partnerships across Germany, the UK, and the US enable multiregional insights spanning early to late-stage disease and variations across markets.

All Flatiron datasets are validated against the company’s rigorous quality standards, reflect real-world clinical practice, and built by expert teams local to each geography, equipping researchers with the depth needed to answer oncology's most pressing questions. Combined with the company’s bladder Panoramic dataset—now spanning the full disease spectrum from early-stage through advanced and metastatic disease—these offerings are a clear answer to persistent evidence gaps across genitourinary cancers.

“The field of prostate cancer is evolving at a rapid pace, changing how care is sequenced from early-stage disease through metastatic CRPC and improving outcomes for patients. Yet critical evidence gaps remain, as we see significant regional variation in how novel therapies are used, and in how uneven access to advanced diagnostics differentially influences treatment decisions,” said Emily Castellanos, MD, MPH, Senior Medical Director and Head of Research Oncology at Flatiron Health. “From a clinical perspective, Flatiron's global Panoramic datasets directly address these evidence gaps, enabling life science companies to increase confidence in decision-making earlier and accelerate development timelines across diseases and geographies, thereby bringing the next generation of precision medicine to all patients sooner.”

This launch marks the first in a series of global dataset expansions, with longitudinal breast cancer and non-small cell lung cancer (NSCLC) datasets planned for 2027. These expansions reinforce Flatiron Health as the gold standard in oncology data, intelligence, and technology. For over a decade, Flatiron has powered the highest-stakes decisions in cancer care and drug development with insights the industry did not have before—shaping what regulators, researchers, clinicians, and biopharma expect from oncology evidence and continuing to redefine that standard. By integrating rigorous real-world data with AI-driven intelligence, Flatiron is doing more than delivering datasets, it is transforming real-world patient experiences into decision-shaping insights that define the future of global cancer care.